Business Segments Jiangsu Hengrui Pharmaceuticals Co.,Ltd
Equities
600276
CNE0000014W7
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.95 CNY | -1.24% |
|
-8.79% | -14.47% |
| 05-15 | Hengrui Pharma Gets China Approval for Lymphoma Drug Trial | MT |
| 05-15 | Hengrui Pharma Gets China Nod for Atopic Dermatitis Drug Trial | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Medicine Manufacturing | 25.91B | 21.28B | 22.82B | 27.98B | 31.63B | |||||
Total Assets | 39.27B | 42.36B | 43.78B | 50.14B | 69.87B | |||||
Interest Expense | -4.71M | -6.49M | -5.9M | -5.56M | -14.35M | |||||
Income Tax Expense | -17.72M | 153M | 389M | 833M | 991M | |||||
CAPEX | -1.66B | -1.99B | -1.48B | -1.97B | -2.96B | |||||
EBT | 4.47B | 3.97B | 4.67B | 7.17B | 8.71B | |||||
D&A | 519M | 569M | 693M | 772M | 843M | |||||
Operating Income | 4.66B | 4.11B | 4.91B | 7.49B | 8.99B | |||||
Net Income | 4.53B | 3.91B | 4.3B | 6.34B | 7.71B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
China | 25.16B | 20.43B | 21.76B | 24.29B | 26.86B | |||||
Foreign | 617M | 779M | 617M | 716M | 4.77B |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition